1. Pilot evaluation of ivacaftor for chronic bronchitis
George M Solomon, Heather Hathorne, Bo Liu, S Vamsee Raju, Ginger Reeves, Edward P Acosta, Mark T Dransfield, Steven M Rowe 
The Lancet Respiratory Medicine 
Volume 4, Issue 6, Pages e32-e33 (June 2016)
DOI: /S (16)
Copyright © 2016 Elsevier Ltd Terms and Conditions

2. Figure
Effect of ivacaftor on functioning of the cystic fibrosis transmembrane conductance regulator and symptoms of chronic bronchitis over the 14 day study period
(A) Change in sweat chloride. Horizontal lines represent mean values. (B) Change in nasal potential difference; change induced by chloride-free solution plus isoprenaline. Horizontal lines represent mean values. (C) Change in BCSS score after 14 days of treatment and after a 14 day washout period. Error bars show the standard error of the mean. The range of BCSS is 1–12, and the minimal clinically important difference is 1 unit. BCSS=Breathlessness, Cough, and Sputum Scale.
The Lancet Respiratory Medicine 2016 4, e32-e33DOI: ( /S (16) )
Copyright © 2016 Elsevier Ltd Terms and Conditions